Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval

Leuk Lymphoma. 2014 Jan;55(1):195-7. doi: 10.3109/10428194.2013.789507. Epub 2013 Jun 12.

Authors

Holly Geyer¹, Keith Cannon, Emily Knight, Veena Fauble, John Camoriano, Robyn Emanuel, Raoul Tibes, Ruben Mesa

Affiliation

¹ Department of Hospital Internal Medicine.

PMID: 23647081
DOI: 10.3109/10428194.2013.789507

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Drug Approval
Humans
Janus Kinases / antagonists & inhibitors
Nitriles
Primary Myelofibrosis / drug therapy*
Pyrazoles / administration & dosage
Pyrazoles / adverse effects
Pyrazoles / therapeutic use*
Pyrimidines
Treatment Outcome
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents
Nitriles
Pyrazoles
Pyrimidines
ruxolitinib
Janus Kinases